Literature DB >> 26033812

Is Progression-Free Survival the Right End Point in Trials of Patients With Clearly Resectable, Borderline Resectable, and Unresectable Liver-Limited Colorectal Cancer?

Claus-Henning Köhne1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26033812     DOI: 10.1200/JCO.2014.60.7044

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

Review 1.  Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.

Authors:  Emily Khoo; Stephen O'Neill; Ewan Brown; Stephen J Wigmore; Ewen M Harrison
Journal:  HPB (Oxford)       Date:  2016-04-20       Impact factor: 3.647

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.